NCT07084896 - Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

April 17, 2025

Study Completion Date

March 11, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Nirogacestat

Nirogacestat will be administered.

Trial Locations (29)

3065

GSK Investigational Site, Fitzroy

11528

GSK Investigational Site, Athens

21565

GSK Investigational Site, Incheon

24105

GSK Investigational Site, Kiel

28041

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

30322

238995, Atlanta

31008

GSK Investigational Site, Madrid

44033

GSK Investigational Site, Ulsan

49546

251164, Grand Rapids

53792

239015, Madison

59037

GSK Investigational Site, Lille

60590

GSK Investigational Site, Frankfurt

94805

GSK Investigational Site, Villejuif

125284

GSK Investigational Site, Moscow

02215

240593, Boston

V5Z1M9

GSK Investigational Site, Vancouver

B3H 1V7

GSK Investigational Site, Halifax

04103

GSK Investigational Site, Leipzig

3584 CX

GSK Investigational Site, Utrecht

0450

GSK Investigational Site, Oslo

40-519

GSK Investigational Site, Katowice

93-513

GSK Investigational Site, Lodz

20-081

GSK Investigational Site, Lublin

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

08916

GSK Investigational Site, Badalona

SE-791 82

GSK Investigational Site, Falun

SE-141 86

GSK Investigational Site, Stockholm